The estimated Net Worth of Venture Opportunity Fund I,... is at least $29 Million dollars as of 1 March 2024. Venture I owns over 46,534 units of Dyne Therapeutics stock worth over $27,624,849 and over the last few years Venture sold DYN stock worth over $1,398,347.
Venture has made over 1 trades of the Dyne Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently Venture sold 46,534 units of DYN stock worth $1,398,347 on 1 March 2024.
The largest trade Venture's ever made was selling 46,534 units of Dyne Therapeutics stock on 1 March 2024 worth over $1,398,347. On average, Venture trades about 46,534 units every 0 days since 2024. As of 1 March 2024 Venture still owns at least 847,388 units of Dyne Therapeutics stock.
You can see the complete history of Venture I stock trades at the bottom of the page.
Over the last 4 years, insiders at Dyne Therapeutics have traded over $197,573,300 worth of Dyne Therapeutics stock and bought 5,790,447 units worth $92,382,301 . The most active insiders traders include Capital Management, L.P.Kol..., Jason P Rhodes und Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $3,566,016. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth $68,914.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics executives and other stock owners filed with the SEC include: